Roundtable on semaglutide mouse data, statins and dementia, and epigenetic aging clocks

Subscribe to our channel: https://www.youtube.com/@mkaeberlein In this episode of Longevity Roundtable for September 2026, I’m joined by Brian Kennedy and Marcus Ranney to dig into some of the biggest recent stories in longevity science and medicine. We start with Marcus fresh off a high-altitude marathon and discuss intermittent hypoxia, hyperoxia, and hyperbaric oxygen therapy. From there, we take a close look at the new mouse lifespan data on semaglutide and what it does, and doesn’t, tell us about GLP-1 drugs and biological aging. We also discuss concerns about GLP-1s and vision loss, and how to think about potential risks in the context of their demonstrated benefits. Then we turn to new evidence linking statin use with reduced dementia risk, the persistent concern that lowering cholesterol could negatively affect the brain, and what the evidence actually suggests. We also tackle a recent Nature Medicine study asking whether epigenetic aging clocks respond to longevity interventions. Can these clocks really tell us whether an intervention is slowing biological aging? And what should we make of the fact that interventions like exercise and rapamycin don't necessarily move them in the direction we might expect? Finally, we discuss Montana’s new Right to Try framework for experimental therapies, why I agreed to serve on its review board, and whether new regulatory models could generate useful clinical data while giving patients greater access to experimental treatments. And, naturally, we finish with Bryan Johnson—because apparently no Longevity Roundtable is complete without him. Topics include: GLP-1 agonists and lifespan, semaglutide, intermittent hypoxia, hyperbaric oxygen, statins and dementia, cholesterol and brain health, epigenetic aging clocks, rapamycin, Right to Try, experimental medicine, and the future of longevity science. DISCLAIMER: The information provided on this channel is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices. More places to find me: Instagram: https://www.instagram.com/mkaeberlein/ LinkedIn: https://www.linkedin.com/in/mkaeberlein/ Twitter: https://twitter.com/mkaeberlein Facebook: https://www.facebook.com/matt.kaeberlein/ --- Hi, I'm Matt Kaeberlein. I spent the first few decades of my career doing scientific research into the biology of aging, trying to understand the finer details of how humans age in order to facilitate translational interventions that promote healthspan and improve quality of life. Now I want to take some of that knowledge out of the lab and into the hands of people who can really use it. On this channel I talk about all things aging and healthspan, from supplements and nutrition to the latest discoveries in longevity research. My goal is to lift the veil on the geroscience and longevity world and help you apply what we know to your own personal health trajectory. I care about quality science and will always be honest about what I don't know. I hope you'll find these episodes helpful!